Sarclisa (isatuximab)

pCPA File Number: 21752

Negotiation Status:

Concluded with an LOI

Indication(s):

Multiple myeloma, relapsed or refractory, in patients who have received 1 to 3 prior lines of therapy (in combination with carfilzomib and dexamethasone)

Sponsor/Manufacturer:

Sanofi Genzyme Canada

CDA-AMC Project Number:

PC0256-000

pCPA Engagement Letter Issued:

2022-05-13

Negotiation Process Concluded:

2023-03-07